Vallerie V McLaughlin

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi End points and clinical trial design in pulmonary arterial hypertension
    Vallerie V McLaughlin
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109 0273, USA
    J Am Coll Cardiol 54:S97-107. 2009
  2. ncbi Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis
    V McLaughlin
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Rheumatology (Oxford) 48:iii25-31. 2009
  3. ncbi Survival with first-line bosentan in patients with primary pulmonary hypertension
    V V McLaughlin
    University of Michigan, 1500 East Medical Center Drive, Women s Hospital, Room L3119, Ann Arbor, MI, USA
    Eur Respir J 25:244-9. 2005
  4. ncbi Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial
    Vallerie V McLaughlin
    University of Michigan Health System, CVC Cardiovascular Medicine, Ann Arbor, Michigan 48109 5853, USA
    J Am Coll Cardiol 55:1915-22. 2010
  5. ncbi Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
    Vallerie V McLaughlin
    The University of Michigan Health System, Ann Arbor, Michigan, USA
    Am J Respir Crit Care Med 174:1257-63. 2006
  6. ncbi Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial
    Melvyn Rubenfire
    University of Michigan, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 0363, USA
    Chest 132:757-63. 2007
  7. ncbi Pulmonary arterial hypertension
    Vallerie V McLaughlin
    University of Michigan Health System, Ann Arbor, MI 48109-0273, USA
    Circulation 114:1417-31. 2006
  8. ncbi Pulmonary hypertension
    Vallerie V McLaughlin
    United Therapeutics
    Curr Probl Cardiol 29:575-634. 2004
  9. ncbi Survival in patients with pulmonary arterial hypertension treated with first-line bosentan
    V V McLaughlin
    Women s Hospital, University of Michigan, Ann Arbor, MI, USA
    Eur J Clin Invest 36:10-5. 2006
  10. ncbi Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension?
    William K Cornwell
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
    Chest 140:697-705. 2011

Detail Information

Publications17

  1. ncbi End points and clinical trial design in pulmonary arterial hypertension
    Vallerie V McLaughlin
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109 0273, USA
    J Am Coll Cardiol 54:S97-107. 2009
    ..Advantages and disadvantages of various trial designs, including placebo-controlled monotherapy or add-on trials, noninferiority studies, and withdrawal trials are also discussed...
  2. ncbi Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis
    V McLaughlin
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Rheumatology (Oxford) 48:iii25-31. 2009
    ..Impaired production of nitric oxide may be addressed by inhibiting phosphodiesterase type-5 with sildenafil or possibly tadalafil. Combinations of multiple targeted therapies may be beneficial to this patient population...
  3. ncbi Survival with first-line bosentan in patients with primary pulmonary hypertension
    V V McLaughlin
    University of Michigan, 1500 East Medical Center Drive, Women s Hospital, Room L3119, Ann Arbor, MI, USA
    Eur Respir J 25:244-9. 2005
    ..First-line bosentan therapy was found to improve survival in patients with advanced primary pulmonary hypertension...
  4. ncbi Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial
    Vallerie V McLaughlin
    University of Michigan Health System, CVC Cardiovascular Medicine, Ann Arbor, Michigan 48109 5853, USA
    J Am Coll Cardiol 55:1915-22. 2010
    ..This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil...
  5. ncbi Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
    Vallerie V McLaughlin
    The University of Michigan Health System, Ann Arbor, Michigan, USA
    Am J Respir Crit Care Med 174:1257-63. 2006
    ..Small, open-label studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH)...
  6. ncbi Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial
    Melvyn Rubenfire
    University of Michigan, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 0363, USA
    Chest 132:757-63. 2007
    ..We determined the relative efficacy of subcutaneous (SC) treprostinil in stable World Health Organization class II and III patients transitioned from IV epoprostenol...
  7. ncbi Pulmonary arterial hypertension
    Vallerie V McLaughlin
    University of Michigan Health System, Ann Arbor, MI 48109-0273, USA
    Circulation 114:1417-31. 2006
  8. ncbi Pulmonary hypertension
    Vallerie V McLaughlin
    United Therapeutics
    Curr Probl Cardiol 29:575-634. 2004
    ..Other forms of pulmonary hypertension, such as pulmonary venous hypertension, pulmonary hypertension related to diseases of the respiratory system, and thromboembolic pulmonary hypertension will be discussed...
  9. ncbi Survival in patients with pulmonary arterial hypertension treated with first-line bosentan
    V V McLaughlin
    Women s Hospital, University of Michigan, Ann Arbor, MI, USA
    Eur J Clin Invest 36:10-5. 2006
    ..The oral dual endothelin (ET(A)/ET(B)) antagonist bosentan has been shown to improve exercise capacity, time to clinical worsening, haemodynamics and quality of life in short-term studies...
  10. ncbi Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension?
    William K Cornwell
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
    Chest 140:697-705. 2011
    ..The objective of this study was to assess the appropriateness of PO-first treatment in patients with WHO FC III PAH...
  11. ncbi Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    Vallerie V McLaughlin
    University of Michigan, 1500 East Medical Center Dr, Women s Hospital Room L3119, Ann Arbor, MI 48109 0273, USA
    Chest 126:78S-92S. 2004
    ..Assessment of prognosis of such patients is important, as it influences both medical therapy and referral for transplantation. This chapter will provide evidence based recommendations to assess the prognosis of patients with PAH...
  12. ncbi Pulmonary diseases and the heart
    MeiLan K Han
    University of Michigan Health System, Ann Arbor, MI, USA
    Circulation 116:2992-3005. 2007
    ....
  13. ncbi Classification and epidemiology of pulmonary hypertension
    Vallerie V McLaughlin
    Pulmonary Hypertension Program, Division of Cardiovascular Medicine, University of Michigan, Woman s RM L3119, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0273, USA
    Cardiol Clin 22:327-41, v. 2004
    ..This article outlines the classification of primary pulmonary hypertension and discusses the various types of the disease...
  14. ncbi Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension
    V F Tapson
    Duke University Medical Center, Durham, NC 27710, USA
    J Vasc Access 7:112-7. 2006
    ..Treprostinil's anti-platelet aggregation characteristics and stability at room temperature may allow for low infusion rates (0.1-0.2 mL/hr) using a miniaturized infusion pump...
  15. ncbi Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
    O Sitbon
    Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Thorax 60:1025-30. 2005
    ....
  16. ncbi Stenting to reverse left ventricular ischemia due to left main coronary artery compression in primary pulmonary hypertension
    S Rich
    Section of Cardiology, Rush Medical College, Chicago, IL 60612-3824, USA
    Chest 120:1412-5. 2001
    ..Stenting of the coronary artery can be done safely with the resolution of these symptoms...
  17. ncbi Severe pulmonary hypertension: critical care clinics
    V V McLaughlin
    Center for Pulmonary Heart Disease, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA
    Crit Care Clin 17:453-67. 2001
    ..A meticulous evaluation is critical. Substantial advances in medical therapy have occurred over the past decade, and the future treatment of this syndrome is promising, with many new medications on the horizon...